References
- DaneseSFiocchiCUlcerative colitisN Engl J Med2011365181713172522047562
- SandsBEFeaganBGRutgeertsPEffects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failedGastroenterology20141473618e3627e324859203
- GilroyLAllenPBIs there a role for vedolizumab in the treatment of ulcerative colitis and Crohn’s disease?Clin Exp Gastroenterol2014716317224899819
- SandbornWJRutgeertsPEnnsRAdalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trialAnn Intern Med20071461282983817470824
- DeleporteAViennotSDupontBEfficacy of anti-TNF-alpha monoclonal antibodies in inflammatory bowel disease treatmentInt J Infereron Cytokine Mediator Res2013201351131
- RosarioMDirksNLGastonguayMRPopulation pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn’s diseaseAliment Pharmacol Ther201542218820225996351
- FeaganBGRutgeertsPSandsBEGEMINI 1 Study GroupVedolizumab as induction and maintenance therapy for ulcerative colitisN Engl J Med2013369869971023964932
- RaineTVedolizumab for inflammatory bowel disease: changing the game, or more of the same?United European Gastroenterol J201425333344
- BresslerBMarshallJKBernsteinCNToronto Ulcerative Colitis Consensus GroupClinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the toronto consensusGastroenterology201514851035e31058e325747596
- DaneseSPanesJDevelopment of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseasesGastroenterology2014147598198925220794
- SolerDChapmanTYangLLWyantTEganRFedykERThe binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseasesJ Pharmacol Exp Ther2009330386487519509315
- MilchCWyantTXuJVedolizumab, a monoclonal antibody to the gut homing alpha4beta7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotypeJ Neuroimmunol20132641–212312624067534
- WyantTLeachTSankohSVedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial resultsGut2015641778324763133
- FeaganBGFeaganBGMcDonaldJWDAn ascending dose trial of a humanized A4B7 antibody in ulcerative colitis (UC)Gastroenterology20001184A874
- FeaganBGGreenbergGRWildGTreatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrinN Engl J Med2005352242499250715958805
- ParikhALeachTWyantTVedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging studyInflamm Bowel Dis20121881470147922147460
- BickstonSJBehmBWTsoulisDJVedolizumab for induction and maintenance of remission in ulcerative colitisCochrane Database Syst Rev20148CD00757125105240
- FeaganBKaserASmythMPanaccioneRSankohSAbhyankarBLong-term efficacy of vedolizumab therapy for patients with ulcerative colitisAm J Gastroenterol2014109suppl 2S477
- SandsBEShafranIFarrayeFAEfficacy and Safety of Retreatment with Vedolizumab in Patients with Ulcerative ColitisViennaEuropean Crohns and Colitis Organization2015
- GovaniSMWaljeeAKHigginsPDAnti-adhesion therapies and the rule of 3 for rare eventsAm J Gastroenterol2013108121831183224300858
- MantzarisGJPrevious cancer and/or lymphoma in patients with refractory IBD–con: anti-TNF or conventional immunosuppressive treatmentDig Dis201432suppl 112212725531364
- LakatosPLMihellerPIs there an increased risk of lymphoma and malignancies under anti-TNF therapy in IBD?Curr Drug Targets201011217918620210767
- DaneseSFiorinoGPeyrin-BirouletLBiological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysisAnn Intern Med20141601070471124842416
- FeaganBColombelJ-FRubinDModyRSankohSLaschKImprovements in Health-Realted Quality of Life in Patients with UC Treated with VedolizumabViennaEuropean Crohns and Colitis foundation2014
- LiuYOzbayABSkupMReichmannWDienerMChaoJComparison of cost per responder and remitter in patients with inflammatory bowel disease in the United States: an indirect comparison of adalimumab and vedolizumabAm Coll Gastroenterol2014109suppl 2S479
- ColombelJFSandbornWJReinischWSONIC Study GroupInfliximab, azathioprine, or combination therapy for Crohn’s diseaseN Engl J Med2010362151383139520393175